KalVista is a pharmaceutical company focused on the discovery, development and commercialization of small molecule protease inhibitors as new treatments for diseases with significant unmet needs.
KalVista is developing plasma kallikrein inhibitors for the treatment of hereditary angioedema (HAE) and diabetic macular edema (DME); indications where excessive plasma kallikrein activity is implicated, but where there remains substantial unmet clinical need. KalVista has built an expanding clinical and advanced pre-clinical product pipeline targeting multiple routes of administration to treat these diseases.
KalVista is advancing several orally delivered plasma kallikrein inhibitors, for the treatment of both HAE and DME, towards clinical testing. KalVista’s most advanced program, an intravitreally administered plasma kallikrein inhibitor, has successfully completed its first-in-human study in patients with DME and is being prepared for Phase 2 clinical studies.
The Company features an R&D team with an established track record in the pharmaceutical development of small molecule protease inhibitors, world-leading expertise in the role of plasma kallikrein in disease, and a management team with proven experience in bringing small molecules through the clinic to commercialization.
The Company is backed by a strong syndicate of international healthcare investors including Longwood Fund, Novo A/S, RA Capital, SV Life Sciences and Venrock. In addition, its development programs have received grant funding from the JDRF, Innovate UK and the European Commission.
KalVista has offices in Salisbury, UK and Cambridge, USA.